June 21, 2021
3 min watch
Save
Genetic testing may pave the way for targeted AML treatment
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Healio spoke with Jonathan M. Gerber, MD, of the Center for Cancer Excellence at the University of Massachusetts Medical School and UMass Memorial Health Care System, and HemOnc Today Editorial Board member, about the clinical implications of the BEAT-AML trial and genetic testing in AML.
Click here to watch the next video in the series on breakthroughs in therapy that he hopes to see in the future.
Published by:
Sources/Disclosures
Collapse
Disclosures:
Gerber served as a principal investigator on a study funded by Janssen evaluating a CD123 bispecific agent and holds a patent (but has not collected royalties) on a leukemia stem cell detection assay for AML.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.